RAC 2.92% $1.94 race oncology ltd

Pillar 1 - FTO (new thread), page-903

  1. 2,658 Posts.
    lightbulb Created with Sketch. 2793
    Checking the details further, the wholesale acquisition cost is 2/3rd's of the monthly revenue per dosage... haven't crunched the numbers yet ~ but on face value seems promising.

    Also timeline, this was two and a bit years to get FDA approval from Phase I (in 2018) including delays due to Covid. So timeline would put ideal timeframe in the 12-18 months conservatively (for partnership / buy-out) if all goes to plan, and Race had a similar circumstances.

    Found it interesting, any other thoughts or comments?
    Last edited by Boffin99: edit 25/04/21
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.